Entity family
Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.
This drug is selected. Its supporting articles are shown below.
…and nasal polyposis 29.2% (12/41). Biologic therapies used were dupilumab 48.7% (20/41), benralizumab 24.4% (10/41), tezepelumab 12.2% (5…
… patients were included (mean age 58.5±13.2 years; 62.7% male). Tezepelumab was used as first-line in 25/52 (48.1%), second-line in 15/52 (…
…umab n=442, dupilumab n=69, mepolizumab n=146, omalizumab n=51, tezepelumab n=69, not recorded n=29. 49.3% of patients were taking maintena…
…0) • Mepolizumab 0 (0) • Benralizumab 1 (9) • Dupilumab 1 (9) • Tezepelumab 6 (55) • None 2 (18) Prior biological therapy use n% 0 4 (36) 1…
… benralizumab, 27.3% to 36.4% for dupilumab, 24.2% to 40.9% for mepolizumab, and 11.1% to 33.3% for omalizumab from Year 1 to Year 3. Basel…
…nts to a novel anti-Thymic Stromal Lympopoetin (TSLP) biologic, Tezepelumab.Methods A retrospective, single-centre analysis was conducted o…
…ogeneous (smoking) real-life patients.Methods Adults initiating mepolizumab or benralizumab between 2017 and 2019 were identified in Belgia…